NCT00012389已完成3 期
A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 试验地点
- 154
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic colorectal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of irinotecan with or without oxaliplatin in treating patients who have metastatic colorectal cancer.
详细描述
OBJECTIVES:
- Compare the overall survival of patients with metastatic colorectal cancer treated with irinotecan with or without oxaliplatin.
- Compare the response rate, time to tumor-related worsening of symptoms, time to disease progression, onset and duration of responses, and duration of disease stabilization in these patients treated with these regimens.
- Compare the safety of these regimens in these patients.
OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to Karnofsky performance status (50-60% vs 70-100%), number of metastatic organs involved (1 vs 2 or more), lactic dehydrogenase (no greater than 1.5 times upper limit of normal (ULN) vs greater than 1.5 times ULN), and prior fluorouracil chemotherapy (adjuvant vs first-line treatment for metastatic disease). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive irinotecan IV over 90 minutes on day 1.
- Arm II: Patients receive oxaliplatin IV over 120 minutes followed by irinotecan IV over 30 minutes on day 1.
Courses repeat in each arm every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed adenocarcinoma of the colon or rectum
- •Metastatic or recurrent disease that is not amenable to potentially curative treatment
- •Progressive or recurrent disease during or after 1, and only 1, regimen of fluorouracil with or without leucovorin calcium or during or within 6 months after adjuvant chemotherapy with fluorouracil and leucovorin calcium
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Karnofsky 50-100%
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- •SGOT/SGPT no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)
- •Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)
- •Creatinine no greater than 1.5 times ULN
- •Cardiovascular:
- •No unstable angina
- •No New York Heart Association class III or IV congestive heart failure
- •No serious cardiac arrhythmia
- •No history of cardiac toxicity from fluorouracil/leucovorin calcium
- •No myocardial infarction within past 6 months
- •No interstitial pneumonia or extensive and symptomatic fibrosis of the lung
- •No uncontrolled predisposing colonic or small bowel disorder
- •No prior chronic enteropathy, chronic diarrhea, or unresolved bowel obstruction/subobstruction
- •No diabetes
- •No active infection
- •No known current peripheral neuropathy
- •No concurrent active cancer except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix
- •No intolerance of appropriate antiemetics
- •No history of anaphylaxis or potential intolerance to atropine sulfate or loperamide
- •Not pregnant or nursing
- •Negative pregnancy test
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •See Disease Characteristics
- •At least 3 weeks since prior chemotherapy
- •No prior irinotecan or oxaliplatin
- •No other prior chemotherapy agents except fluorouracil with or without leucovorin calcium as first-line therapy for metastatic disease or in the adjuvant setting
- •Endocrine therapy:
- •Not specified
- •Radiotherapy:
- •Prior radiotherapy to non-target lesions allowed
- •No prior radiotherapy to target lesions unless disease progression is documented within the radiation port
- •At least 3 weeks since prior radiotherapy
- •At least 4 weeks since prior major surgical procedure and recovered
- •Prior surgery for primary tumor or metastasis allowed
- 另有 2 项未显示
排除标准
- 未提供
研究者
研究点 (154)
Loading locations...
相似试验
Unknown
3 期
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00008281Sanofi
撤回
2 期
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung CancerLung CancerNCT00006374Case Comprehensive Cancer Center
已完成
2 期
Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue SarcomaSarcomaNCT00052390Memorial Sloan Kettering Cancer Center
已完成
3 期
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerPancreatic CancerNCT00023972Daiichi Sankyo
已完成
3 期
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00004252Pfizer